Health Care & Life Sciences » Biotechnology | Neptune Technologies & Bioressources Inc.

Neptune Technologies & Bioressources Inc. | Income Statement

Fiscal year is April-March. All values CAD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
19,496.00
15,069.90
22,632.40
43,216.20
27,645.60
24,442
Cost of Goods Sold (COGS) incl. D&A
17,327.20
23,458.90
18,573.10
32,831.80
23,795.50
19,883.90
Gross Income
2,168.80
8,389.00
4,059.30
10,384.40
3,850.00
4,558.10
SG&A Expense
40,172.40
32,967.30
19,978.30
18,913.20
24,629.70
19,523.50
EBIT
38,003.70
41,356.30
15,919.00
8,528.80
20,779.60
14,965.40
Unusual Expense
15,214.40
9,904.30
2,798.10
15,038.60
36.30
7,930.40
Non Operating Income/Expense
1,273.80
2,197.60
1,319.10
1,163.90
32,296.80
12
Interest Expense
1,205.40
871.30
1,446.00
2,551.80
2,257.20
455.10
Pretax Income
22,620.00
29,972.10
13,141.40
2,855.60
9,451.10
23,104.30
Income Tax
382.60
149.80
2,311.70
2,043.40
111.80
87.40
Consolidated Net Income
22,237.50
29,822.30
10,829.70
812.20
9,339.40
23,191.70
Net Income
16,640.00
27,960.50
7,470.00
6,381.50
17,530.90
23,191.70
Net Income After Extraordinaries
16,640.00
27,960.50
7,470.00
6,381.50
17,530.90
23,191.70
Net Income Available to Common
16,640.00
27,960.50
7,470.00
6,381.50
17,530.90
23,191.70
EPS (Basic)
0.27
0.38
0.10
0.07
0.22
0.29
Basic Shares Outstanding
60,820.10
74,550.10
75,735.60
77,945.50
78,599.20
79,540
EPS (Diluted)
0.27
0.38
0.10
0.09
0.22
0.29
Diluted Shares Outstanding
60,820.10
74,550.10
75,735.60
78,145.90
79,359.30
79,540
EBITDA
37,650.70
39,637.60
13,339.40
5,005.60
17,237.80
11,909.10
Non-Operating Interest Income
100.90
153.60
106.30
61.40
227.50
234.70
Minority Interest Expense
5,597.50
1,861.70
3,359.70
5,569.30
8,191.50
-

About Neptune Technologies & Bioressources

View Profile
Address
545, Promenade du Centropolis
Laval Qu├ębec H7T 0A3
Canada
Employees -
Website http://www.neptunecorp.com
Updated 07/08/2019
Neptune Technologies & Bioresources, Inc. engages in the development and commercialization specialty ingredients. It offers the MaxSimil a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. It operates through the Nutraceutical, Cannabis, and Cardiovascular segments.